Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

ACE: A Workbench Using Evolutionary Genetic Algorithms for Analyzing Association in TCGA.

Gilmore AR, Alderdice M, Savage KI, O'Reilly PG, Roddy AC, Dunne PD, Lawler M, McDade SS, Waugh DJ, McArt DG.

Cancer Res. 2019 Apr 15;79(8):2072-2075. doi: 10.1158/0008-5472.CAN-18-1976. Epub 2019 Feb 13.

PMID:
30760519
2.

Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists.

McCann C, Crawford N, Majkut J, Holohan C, Armstrong CWD, Maxwell PJ, Ong CW, LaBonte MJ, McDade SS, Waugh DJ, Longley DB.

Cell Death Dis. 2018 Oct 22;9(11):1081. doi: 10.1038/s41419-018-1125-5.

3.

Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer.

Armstrong CWD, Lyubomska O, LaBonte MJ, Waugh DJJ.

Methods Mol Biol. 2018;1786:195-206. doi: 10.1007/978-1-4939-7845-8_11.

PMID:
29786794
4.

Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.

Jain S, Lyons CA, Walker SM, McQuaid S, Hynes SO, Mitchell DM, Pang B, Logan GE, McCavigan AM, O'Rourke D, McArt DG, McDade SS, Mills IG, Prise KM, Knight LA, Steele CJ, Medlow PW, Berge V, Katz B, Loblaw DA, Harkin DP, James JA, O'Sullivan JM, Kennedy RD, Waugh DJ.

Ann Oncol. 2018 Jan 1;29(1):215-222. doi: 10.1093/annonc/mdx637.

5.

Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.

Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW, Clarke NW, Kennedy RD.

Eur Urol. 2017 Oct;72(4):509-518. doi: 10.1016/j.eururo.2017.03.027. Epub 2017 Apr 10.

6.

Expanding the Armamentarium for Castrate-resistant Prostate Cancer.

Waugh DJ.

Eur Urol. 2017 Mar;71(3):328-329. doi: 10.1016/j.eururo.2016.05.022. Epub 2016 May 24. No abstract available.

PMID:
27234999
7.

Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer.

Dunne PD, McArt DG, Bradley CA, O'Reilly PG, Barrett HL, Cummins R, O'Grady T, Arthur K, Loughrey MB, Allen WL, McDade SS, Waugh DJ, Hamilton PW, Longley DB, Kay EW, Johnston PG, Lawler M, Salto-Tellez M, Van Schaeybroeck S.

Clin Cancer Res. 2016 Aug 15;22(16):4095-104. doi: 10.1158/1078-0432.CCR-16-0032. Epub 2016 May 5.

8.

PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.

Armstrong CW, Maxwell PJ, Ong CW, Redmond KM, McCann C, Neisen J, Ward GA, Chessari G, Johnson C, Crawford NT, LaBonte MJ, Prise KM, Robson T, Salto-Tellez M, Longley DB, Waugh DJ.

Oncotarget. 2016 Feb 16;7(7):7885-98. doi: 10.18632/oncotarget.6955.

9.

Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program.

Lawler M, Gavin A, Salto-Tellez M, Kennedy RD, Van Schaeybroeck S, Wilson RH, Harkin DP, Grayson M, Boyd RE, Hamilton PW, McArt DG, James J, Robson T, Ladner RD, Prise KM, O'Sullivan JM, Harrison T, Murray L, Johnston PG, Waugh DJ.

Cancer. 2016 Mar 1;122(5):664-73. doi: 10.1002/cncr.29814. Epub 2015 Dec 22. No abstract available.

10.

CD44-mediated activation of α5β1-integrin, cortactin and paxillin signaling underpins adhesion of basal-like breast cancer cells to endothelium and fibronectin-enriched matrices.

McFarlane S, McFarlane C, Montgomery N, Hill A, Waugh DJ.

Oncotarget. 2015 Nov 3;6(34):36762-73. doi: 10.18632/oncotarget.5461.

11.

The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers.

Ong CW, Chong PY, McArt DG, Chan JY, Tan HT, Kumar AP, Chung MC, Clément MV, Soong R, Van Schaeybroeck S, Waugh DJ, Johnston PG, Dunne PD, Salto-Tellez M.

Oncotarget. 2015 May 20;6(14):12763-73.

12.

CD44 increases the efficiency of distant metastasis of breast cancer.

McFarlane S, Coulter JA, Tibbits P, O'Grady A, McFarlane C, Montgomery N, Hill A, McCarthy HO, Young LS, Kay EW, Isacke CM, Waugh DJ.

Oncotarget. 2015 May 10;6(13):11465-76.

13.
14.

TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.

D'Costa ZC, Higgins C, Ong CW, Irwin GW, Boyle D, McArt DG, McCloskey K, Buckley NE, Crawford NT, Thiagarajan L, Murray JT, Kennedy RD, Mulligan KA, Harkin DP, Waugh DJ, Scott CJ, Salto-Tellez M, Williams R, Mullan PB.

Oncotarget. 2014 Mar 30;5(6):1609-20.

15.

Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer.

Campbell LM, Maxwell PJ, Waugh DJ.

Pharmaceuticals (Basel). 2013 Aug 6;6(8):929-59. doi: 10.3390/ph6080929.

16.

Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis.

McCourt CM, McArt DG, Mills K, Catherwood MA, Maxwell P, Waugh DJ, Hamilton P, O'Sullivan JM, Salto-Tellez M.

PLoS One. 2013 Jul 26;8(7):e69604. doi: 10.1371/journal.pone.0069604. Print 2013.

17.

SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma.

Crawford N, Stasik I, Holohan C, Majkut J, McGrath M, Johnston PG, Chessari G, Ward GA, Waugh DJ, Fennell DA, Longley DB.

Cell Death Dis. 2013 Jul 18;4:e733. doi: 10.1038/cddis.2013.258.

18.

Ex vivo expansion of human outgrowth endothelial cells leads to IL-8-mediated replicative senescence and impaired vasoreparative function.

Medina RJ, O'Neill CL, O'Doherty TM, Chambers SE, Guduric-Fuchs J, Neisen J, Waugh DJ, Simpson DA, Stitt AW.

Stem Cells. 2013 Aug;31(8):1657-68. doi: 10.1002/stem.1414.

19.

Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.

Maxwell PJ, Coulter J, Walker SM, McKechnie M, Neisen J, McCabe N, Kennedy RD, Salto-Tellez M, Albanese C, Waugh DJ.

Eur Urol. 2013 Aug;64(2):177-88. doi: 10.1016/j.eururo.2012.08.032. Epub 2012 Aug 28.

20.

Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response.

Ming L, Byrne NM, Camac SN, Mitchell CA, Ward C, Waugh DJ, McKeown SR, Worthington J.

Int J Cancer. 2013 Mar 15;132(6):1323-32. doi: 10.1002/ijc.27796. Epub 2012 Nov 23.

21.

Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.

McCourt C, Maxwell P, Mazzucchelli R, Montironi R, Scarpelli M, Salto-Tellez M, O'Sullivan JM, Longley DB, Waugh DJ.

Clin Cancer Res. 2012 Jul 15;18(14):3822-33. doi: 10.1158/1078-0432.CCR-11-3277. Epub 2012 May 23.

22.

CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity.

Montgomery N, Hill A, McFarlane S, Neisen J, O'Grady A, Conlon S, Jirstrom K, Kay EW, Waugh DJ.

Breast Cancer Res. 2012 May 23;14(3):R84.

23.

Constitutive and treatment-induced CXCL8-signalling selectively modulates the efficacy of anti-metabolite therapeutics in metastatic prostate cancer.

Wilson C, Maxwell PJ, Longley DB, Wilson RH, Johnston PG, Waugh DJ.

PLoS One. 2012;7(5):e36545. doi: 10.1371/journal.pone.0036545. Epub 2012 May 9.

24.

FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.

Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H, McKeen H, Waugh DJ, Roberts J, McGregor J, Cotton G, James I, Harrison T, Hirst DG, Robson T.

Clin Cancer Res. 2011 Mar 1;17(5):1044-56. doi: 10.1158/1078-0432.CCR-10-2241. Epub 2011 Mar 1.

25.

The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue.

Oladipo O, Conlon S, O'Grady A, Purcell C, Wilson C, Maxwell PJ, Johnston PG, Stevenson M, Kay EW, Wilson RH, Waugh DJ.

Br J Cancer. 2011 Feb 1;104(3):480-7. doi: 10.1038/sj.bjc.6606055.

26.

Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.

Seaton A, Maxwell PJ, Hill A, Gallagher R, Pettigrew J, Wilson RH, Waugh DJ.

Br J Cancer. 2009 Nov 3;101(9):1620-9. doi: 10.1038/sj.bjc.6605356. Epub 2009 Oct 6.

27.

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer.

Wilson C, Scullin P, Worthington J, Seaton A, Maxwell P, O'Rourke D, Johnston PG, McKeown SR, Wilson RH, O'Sullivan JM, Waugh DJ.

Br J Cancer. 2008 Dec 16;99(12):2054-64. doi: 10.1038/sj.bjc.6604804. Epub 2008 Dec 2.

28.

The interleukin-8 pathway in cancer.

Waugh DJ, Wilson C.

Clin Cancer Res. 2008 Nov 1;14(21):6735-41. doi: 10.1158/1078-0432.CCR-07-4843. Review.

29.

Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells.

Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ.

Mol Cancer Ther. 2008 Sep;7(9):2649-61. doi: 10.1158/1535-7163.MCT-08-0148.

30.

Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis.

Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM, Wilson RH, Johnston PG, Waugh DJ.

J Pharmacol Exp Ther. 2008 Dec;327(3):746-59. doi: 10.1124/jpet.108.143826. Epub 2008 Sep 9.

PMID:
18780829
31.

Multi-faceted roles for CXC-chemokines in prostate cancer progression.

Waugh DJ, Wilson C, Seaton A, Maxwell PJ.

Front Biosci. 2008 May 1;13:4595-604. Review.

PMID:
18508531
32.

Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.

Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ.

Carcinogenesis. 2008 Jun;29(6):1148-56. doi: 10.1093/carcin/bgn109. Epub 2008 May 16.

PMID:
18487223
33.

Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells.

MacManus CF, Pettigrew J, Seaton A, Wilson C, Maxwell PJ, Berlingeri S, Purcell C, McGurk M, Johnston PG, Waugh DJ.

Mol Cancer Res. 2007 Jul;5(7):737-48. Epub 2007 Jul 2.

34.

HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.

Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG, Waugh DJ.

Oncogene. 2007 Nov 15;26(52):7333-45. Epub 2007 May 28.

PMID:
17533374
35.

Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells.

Hill A, McFarlane S, Mulligan K, Gillespie H, Draffin JE, Trimble A, Ouhtit A, Johnston PG, Harkin DP, McCormick D, Waugh DJ.

Oncogene. 2006 Oct 5;25(45):6079-91. Epub 2006 May 1.

PMID:
16652145
36.

The emerging role of CD44 in regulating skeletal micrometastasis.

Hill A, McFarlane S, Johnston PG, Waugh DJ.

Cancer Lett. 2006 Jun 8;237(1):1-9. Epub 2005 Jun 27. Review.

PMID:
15979783
37.

Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer.

Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, Montironi R, Waugh DJ.

Clin Cancer Res. 2005 Jun 1;11(11):4117-27.

38.

CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells.

Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ.

Cancer Res. 2004 Aug 15;64(16):5702-11.

39.

Modifications to the N-terminus but not the C-terminus of calcitonin gene-related peptide(8-37) produce antagonists with increased affinity.

Smith DD, Saha S, Fang G, Schaffert C, Waugh DJ, Zeng W, Toth G, Hulce M, Abel PW.

J Med Chem. 2003 Jun 5;46(12):2427-35.

PMID:
12773046
40.

Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists.

Waugh DJ, Gaivin RJ, Zuscik MJ, Gonzalez-Cabrera P, Ross SA, Yun J, Perez DM.

J Biol Chem. 2001 Jul 6;276(27):25366-71. Epub 2001 Apr 30.

41.

Hypotension, autonomic failure, and cardiac hypertrophy in transgenic mice overexpressing the alpha 1B-adrenergic receptor.

Zuscik MJ, Chalothorn D, Hellard D, Deighan C, McGee A, Daly CJ, Waugh DJ, Ross SA, Gaivin RJ, Morehead AJ, Thomas JD, Plow EF, McGrath JC, Piascik MT, Perez DM.

J Biol Chem. 2001 Apr 27;276(17):13738-43. Epub 2001 Feb 1.

42.

Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy.

Zuscik MJ, Sands S, Ross SA, Waugh DJ, Gaivin RJ, Morilak D, Perez DM.

Nat Med. 2000 Dec;6(12):1388-94.

PMID:
11100125
43.
44.

Regulation of the cellular localization and signaling properties of the alpha(1B)- and alpha(1D)-adrenoceptors by agonists and inverse agonists.

McCune DF, Edelmann SE, Olges JR, Post GR, Waldrop BA, Waugh DJ, Perez DM, Piascik MT.

Mol Pharmacol. 2000 Apr;57(4):659-66.

PMID:
10727510
45.

Binding, partial agonism, and potentiation of alpha(1)-adrenergic receptor function by benzodiazepines: A potential site of allosteric modulation.

Waugh DJ, Gaivin RJ, Damron DS, Murray PA, Perez DM.

J Pharmacol Exp Ther. 1999 Dec;291(3):1164-71.

PMID:
10565838
46.

Limitations in using peptide drugs to characterize calcitonin gene-related peptide receptors.

Waugh DJ, Bockman CS, Smith DD, Abel PW.

J Pharmacol Exp Ther. 1999 Jun;289(3):1419-26.

PMID:
10336535
47.
49.

Structure-activity studies on position 14 of human alpha-calcitonin gene-related peptide.

Li J, Matsuura JE, Waugh DJ, Adrian TE, Abel PW, Manning MC, Smith DD.

J Med Chem. 1997 Sep 12;40(19):3071-6.

PMID:
9301670

Supplemental Content

Loading ...
Support Center